Novel immunotherapeutic approaches in head and neck cancer

Abstract

Unresectable recurrent or metastatic head and neck cancer is an incurable disease with survival of approximately 12 months. Head and neck tumors exhibit numerous derangements in the tumor microenvironment that aid in immune evasion and may serve as targets for future therapies. Pembrolizumab is now approved as a first line therapy. Despite the promise of currently approved immunotherapies there continues to be low response rates and additional strategies are needed. Here, alterations in the immune microenvironment and current therapeutic strategies are reviewed with a focus on novel immunologic approaches.

Keywords

Immunotherapy / head and neck / immune evasion / immune derangement / checkpoint inhibitors / recurrent/metastatic

References

[1] Ferlay J,Dikshit R,Mathers C.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012..Int J Cancer2015;136:E359-86

[2] Chaturvedi AK,Pfeiffer RM,Xiao W.Human papillomavirus and rising oropharyngeal cancer incidence in the United States..J Clin Oncol2011;29:4294-301 PMCID:PMC3221528

[3] Argiris A,Raben D.Head and neck cancer. Lancet..Lancet2008;371:1695-709

[4] Forastiere AA,Maor M,Weber R.Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer..N Engl J Med2003;349:2091-8

[5] Taneja C,Koness RJ,Wanebo HJ.Changing patterns of failure of head and neck cancer..Arch Otolaryngol Head Neck Surg2002;128:324-7

[6] Baxi S,Ganly I,Pfister DG.Ten years of progress in head and neck cancers..J Natl Compr Cancer Netw2012;10:806-10 PMCID:PMC3708312

[7] Ferris RL,Fayette J,Gillison ML.Nivolumab for recurrent squamous-cell carcinoma of the head and neck..N Engl J Med2016;375:1856-67 PMCID:PMC5564292

[8] Seiwert TY,Mehra R,Berger R.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial..Lancet Oncol2016;17:956-65

[9] US Food and Drug. FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-first-line-treatment-head-and-neck-squamous-cell-carcinoma [Last accessed on 12 Nov 2019]

[10] Chen DS.Oncology meets immunology: the cancer-immunity cycle..Immunity2013;39:1-10

[11] Mellman I,Dranoff G.Cancer immunotherapy comes of age..Nature2011;480:480-9 PMCID:PMC3967235

[12] Blankenstein T,Gilboa E.The determinants of tumour immunogenicity..Nat Rev Cancer2012;12:307-13 PMCID:PMC3552609

[13] Champiat S,Lebel-Binay S,Soria JC.Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy..Oncoimmunology2014;3:e27817 PMCID:PMC3937193

[14] Lawrence MS,Polak P,Cibulskis K.Mutational heterogeneity in cancer and the search for new cancer-associated genes..Nature2013;499:214-8 PMCID:PMC3919509

[15] Cannataro VL,Sasaki T,Grewal NKS.APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma..Oncogene2019;38:3475-87 PMCID:PMC6499643

[16] Gensterblum-Miller E.Protecting tumors by preventing human papilloma virus antigen presentation: insights from emerging bioinformatics algorithms..Cancers (Basel)2019;11:E1543 PMCID:PMC6826432

[17] Sharon H.Identifying neoantigens for use in immunotherapy..Mamm Genome2018;29:714-30 PMCID:PMC6267674

[18] Lee CH,Jooss K.Update on tumor neoantigens and their utility: why it is good to be Different..Trends Immunol2018;39:536-48

[19] Soria-Guerra RE,Govea-Alonso DO.An overview of bioinformatics tools for epitope prediction: implications on vaccine development..J Biomed Inform2015;53:405-14

[20] Concha-Benavente F,Ferrone S.Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells..Oral Oncol2016;58:52-8 PMCID:PMC5264518

[21] Ferris RL,Ferrone S.Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance..Immunol Res2005;33:113-33

[22] Campo MS,Cortese MS,Araibi EH.HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells..Virology2010;407:137-42

[23] Cicchini L,Westrich JA,Warren CJ.High-risk human papillomavirus E7 alters host DNA methylome and represses HLA-E expression in human keratinocytes..Sci Rep2017;7:3633 PMCID:PMC5473897

[24] de Freitas AC,Barros MR Jr.hrHPV E5 oncoprotein: immune evasion and related immunotherapies..J Exp Clin Cancer Res2017;36:71 PMCID:PMC5445378

[25] Meissner M,Kunkel M,Whiteside TL.Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome..Clin Cancer Res2005;11:2552-60

[26] Ogino T,Ishii H,Miyokawa N.HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker..Cancer Res2006;66:9281-9

[27] Moy JD,Ferris RL.Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma..Eur J Cancer2017;76:152-66 PMCID:PMC5459368

[28] Rudd CE,Schneider H.CD28 and CTLA-4 coreceptor expression and signal transduction..Immunol Rev2009;229:12-26 PMCID:PMC4186963

[29] Ariffin AB,Jahangeer S,Hinchion J.Releasing pressure in tumors: what do we know so far and where do we go from here? A review..Cancer Res2014;74:2655-62

[30] Farsaci B,Coplin MA,Lepone LM.Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines..Cancer Immunol Res2014;2:1090-102 PMCID:PMC4221465

[31] Hamzah J,Kiessling F,Manzur M.Vascular normalization in Rgs5-deficient tumours promotes immune destruction..Nature2008;453:410-4

[32] Allen CT,Van Waes C.Anti-tumor immunity in head and neck cancer: understanding the evidence, how tumors escape and immunotherapeutic approaches..Cancers2015;7:2397-414 PMCID:PMC4695900

[33] Economopoulou P,Giotakis EI.The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications..Ann Transl Med2016;4:173 PMCID:PMC4876265

[34] Fujii N,Shiomi T,Takeda C.Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance..J Oral Pathol Med2012;41:444-51

[35] Spanos WC,Harris GF,Strand GL.The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth..J Virol2008;82:2493-500 PMCID:PMC2258903

[36] Long GV,Hamid O,Caglevic C.Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study..Lancet Oncol2019;20:1083-97

[37] Califano JA,Noonan KA,Zhang Z.Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma..Clin Cancer Res2015;21:30-8 PMCID:PMC4329916

[38] Vasquez-Dunddel D,Zeng Q,Albesiano E.STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients..J Clin Invest2013;123:1580-9 PMCID:PMC3613901

[39] Hoesli R,Rosko AJ,Chow KL.Proportion of CD4 and CD8 tumor infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal squamous cell carcinoma..Oral Oncol2018;77:83-9 PMCID:PMC5897103

[40] Mandal R,Desrichard A,Dalin MG.The head and neck cancer immune landscape and its immunotherapeutic implications..JCI Insight2016;1:e89829 PMCID:PMC5070962

[41] Ono T,Kawahara A,Hattori S.Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma..Oncotarget2017;8:92699-714 PMCID:PMC5696215

[42] Young MR,Lozano Y,Benefield J.Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells..Int J Cancer1997;74:69-74

[43] Chen L.Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity..Nat Rev Immunol2004;4:336-47

[44] Diamond MS,Matsushita H,Dunn GP.Type I interferon is selectively required by dendritic cells for immune rejection of tumors..J Exp Med2011;208:1989-2003 PMCID:PMC3182061

[45] Fuertes MB,Kline J,Kranz DM.Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8 {alpha}+ dendritic cells..J Exp Med2011;208:2005-16 PMCID:PMC3182064

[46] Zandberg DP.The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck..Oral Oncol2014;50:627-32

[47] Zou W,Chen L.PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations..Sci Transl Med2016;8:328 PMCID:PMC4859220

[48] Chen L.Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future..J Clin Invest2015;125:3384-91 PMCID:PMC4588282

[49] Badoual C,Merillon N,Ravel P.PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer..Cancer Res2013;73:128-38

[50] Lyford-Pike S,Young GD,Westra WH.Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma..Cancer Res2013;73:1733-41 PMCID:PMC3602406

[51] Ukpo OC,Lewis JS Jr.B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma..Head Neck Pathol2013;7:113-21 PMCID:PMC3642256

[52] Tran L,Xiao R,Davis R.Cisplatin alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma..Cancer Immunol Res2017;5:1141-51 PMCID:PMC5712281

[53] de Biasi AR,Adusumilli PS.Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence..Clin Cancer Res2014;20:5384-91 PMCID:PMC4216745

[54] Hato SV,de Vries IJ.Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics..Clin Cancer Res2014;20:2831-7

[55] Reits EA,Herberts CA,Chakraborty M.Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy..J Exp Med2006;203:1259-71 PMCID:PMC3212727

[56] Klein B,Lurie H,Nyska A.The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture..J Neurosurg1994;80:1074-7

[57] Santin AD,Fruehauf J,Pecorelli S.Effects of irradiation on the expression of surface antigens in human ovarian cancer..Gynecol Oncol1996;60:468-74

[58] Santin AD,Hiserodt JC,Eck LM.Effects of cytokines combined with high-dose gamma irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule-1 in human ovarian cancers..Int J Cancer1996;65:688-94

[59] Lugade AA,Gerber SA,Frelinger JG.Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor..J Immunol2005;174:7516-23

[60] Manukian G,Lu B,Johnson JM.Combining radiation and immune checkpoint blockade in the treatment of head and neck squamous cell carcinoma..Front Oncol2019;9:122 PMCID:PMC6414812

[61] Abuodeh Y,Kim S.Systematic review of case reports on the abscopal effect..Curr Probl Cancer2016;40:25-37

[62] Postow MA,Barker CA,Yuan J.Immunologic correlates of the abscopal effect in a patient with melanoma..New Engl J Med2012;366:925-31 PMCID:PMC3345206

[63] Jie HB,Lee SC,Argiris A.CTLA-4(+) regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis..Cancer Res2015;75:2200-10 PMCID:PMC4452385

[64] Concha-Benavente F,Trivedi S,Chandran U.Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNgamma that induce PD-L1 expression in head and neck cancer..Cancer Res2016;76:1031-43 PMCID:PMC4775348

[65] Pahl JH,Buddingh EP,Szuhai K.Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma..Clin Cancer Res2012;18:432-41

[66] Lee J.Current status of experimental therapeutics for head and neck cancer..Exp Biol Med2011;236:375-89

[67] Roberti MP,Bravo AI,Arriaga JM.IL-15 and IL-2 increase cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR..Breast Cancer Res Treat2011;130:465-75

[68] Hsu YF,Corrales L,Gurpide A.Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo..Mol Cancer2010;9:139 PMCID:PMC2893457

[69] Srivastava RM,Andrade Filho PA,Jie HB.Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients..Clin Cancer Res2013;19:1858-72 PMCID:PMC3640274

[70] Cohen EEW,Le Tourneau C,Licitra L.Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study..Lancet2019;393:156-67

[71] Rischin D,Greil R,Tahara M.Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)..J Clin Oncol2019;37:6000

[72] Colevas AD,Braiteh F,Brana I.Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial..Ann Oncol2018;29:2247-53

[73] Segal NH,Balmanoukian A,Massarelli E.Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort..Eur J Cancer2019;109:154-61

[74] Licitra LF,Even C,Dvorkin M.EAGLE: a phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)..J Clin Oncol2019;37:6012

[75] Pak AS,Matthews JP,Petruzzelli GJ.Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor..Clin Cancer Res1995;1:95-103

[76] Serafini P,Kelso M,Califano J.Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function..J Exp Med2006;203:2691-702 PMCID:PMC2118163

[77] Komiya T.Updates in the clinical development of epacadostat and other indoleamine 2,3-dioxygenase 1 inhibitors (IDO1) for human cancers..Front Oncol2018;8:423 PMCID:PMC6180183

[78] Gadhikar MA.Recent advances in head and neck cancer: the beginning of the immunotherapy era in HNSCC..Adv Mod Oncol Res2018;4:

[79] Newick K,Moon E.CAR T cell therapy for solid tumors..Ann Rev Med2017;68:139-52

[80] Ohtani T,Furuhashi A,Nakamura S.Activated cytotoxic T-lymphocyte immunotherapy is effective for advanced oral and maxillofacial cancers..Int J Oncol2014;45:2051-7